168 related articles for article (PubMed ID: 11812917)
21. Epoetin alfa. A review of its clinical efficacy in the management of anaemia associated with renal failure and chronic disease and its use in surgical patients.
Dunn CJ; Wagstaff AJ
Drugs Aging; 1995 Aug; 7(2):131-56. PubMed ID: 7579784
[TBL] [Abstract][Full Text] [Related]
22. Management of cancer-related anemia: epoetin alfa and quality of life.
Soignet S
Semin Hematol; 2000 Oct; 37(4 Suppl 6):9-13. PubMed ID: 11068950
[TBL] [Abstract][Full Text] [Related]
23. Clinical experience with epoetin alfa in the management of hemoglobin levels in orthopedic surgery and cancer. Implications for use in gynecologic surgery.
Stovall TG
J Reprod Med; 2001 May; 46(5 Suppl):531-8. PubMed ID: 11396387
[TBL] [Abstract][Full Text] [Related]
24. Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy.
Fallowfield L; Gagnon D; Zagari M; Cella D; Bresnahan B; Littlewood TJ; McNulty P; Gorzegno G; Freund M;
Br J Cancer; 2002 Dec; 87(12):1341-53. PubMed ID: 12454760
[TBL] [Abstract][Full Text] [Related]
25. Once-weekly epoetin beta therapy in patients with solid tumours and chemotherapy-induced anaemia: a randomized, double-blind, dose-finding study.
Heras P; Kritikos K; Hatzopoulos A; Mitsibounas D
Eur J Cancer Care (Engl); 2008 Nov; 17(6):619-23. PubMed ID: 18707619
[TBL] [Abstract][Full Text] [Related]
26. Comparing the efficacy and safety of fixed versus weight-based dosing of epoetin alpha in anemic cancer patients receiving platinum-based chemotherapy.
Granetto C; Ricci S; Martoni A; Pezzella G; Testore F; Mattioli R; Lampignano M; Tacconi F; Porrozzi S; Gasparini G; Mantovani G;
Oncol Rep; 2003; 10(5):1289-96. PubMed ID: 12883695
[TBL] [Abstract][Full Text] [Related]
27. Epoetin alfa and epoetin beta: new indication. Treatment of anaemia due to cytotoxic chemotherapy.
Prescrire Int; 2002 Apr; 11(58):39-43. PubMed ID: 11987310
[TBL] [Abstract][Full Text] [Related]
28. Standard of care for cancer-related anemia: improving hemoglobin levels and quality of life.
Cortesi E; Gascón P; Henry D; Littlewood T; Milroy R; Pronzato P; Reinhardt U; Shasha D; Thatcher N; Wilkinson P
Oncology; 2005; 68 Suppl 1():22-32. PubMed ID: 15855813
[TBL] [Abstract][Full Text] [Related]
29. Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy.
O'Shaughnessy JA; Vukelja SJ; Holmes FA; Savin M; Jones M; Royall D; George M; Von Hoff D
Clin Breast Cancer; 2005 Feb; 5(6):439-46. PubMed ID: 15748464
[TBL] [Abstract][Full Text] [Related]
30. A new dose-intense epoetin alfa regimen effective in anemic cancer patients receiving chemotherapy: an open-label, non randomized, pilot study.
Santini D; Vincenzi B; La Cesa A; Virzi V; Navajas F; Malafarina V; Dicuonzo G; Cassandro R; Esposito V; Montesarchio V; Groeger AM; Tonini G
Anticancer Res; 2005; 25(1B):669-74. PubMed ID: 15816644
[TBL] [Abstract][Full Text] [Related]
31. Early Intervention with epoetin alfa during platinum-based chemotherapy: an analysis of quality-of-life results of a multicenter, randomized, controlled trial compared with population normative data.
Savonije JH; van Groeningen CJ; Wormhoudt LW; Giaccone G
Oncologist; 2006 Feb; 11(2):197-205. PubMed ID: 16476840
[TBL] [Abstract][Full Text] [Related]
32. A comparison between once-weekly and twice- or thrice-weekly subcutaneous injection of epoetin alfa: results from a randomized controlled multicentre study.
Lee YK; Kim SG; Seo JW; Oh JE; Yoon JW; Koo JR; Kim HJ; Noh JW
Nephrol Dial Transplant; 2008 Oct; 23(10):3240-6. PubMed ID: 18469158
[TBL] [Abstract][Full Text] [Related]
33. The evolving role of epoetin alfa in cancer therapy.
Henry DH
Oncologist; 2004; 9(1):97-107. PubMed ID: 14755019
[TBL] [Abstract][Full Text] [Related]
34. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
[TBL] [Abstract][Full Text] [Related]
35. Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population.
Cella D; Zagari MJ; Vandoros C; Gagnon DD; Hurtz HJ; Nortier JW
J Clin Oncol; 2003 Jan; 21(2):366-73. PubMed ID: 12525531
[TBL] [Abstract][Full Text] [Related]
36. Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy.
Littlewood TJ; Nortier J; Rapoport B; Pawlicki M; de Wasch G; Vercammen E; Schuette W; Wils J; Freund M;
Hematol Oncol; 2003 Dec; 21(4):169-80. PubMed ID: 14735555
[TBL] [Abstract][Full Text] [Related]
37. Benefits of epoetin alfa in anemic breast cancer patients receiving chemotherapy.
Demetri GD; Gabrilove JL; Blasi MV; Hill RJ; Glaspy J
Clin Breast Cancer; 2002 Apr; 3(1):45-51. PubMed ID: 12020395
[TBL] [Abstract][Full Text] [Related]
38. Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly.
Cartenì G; Giannetta L; Ucci G; De Signoribus G; Vecchione A; Pinotti G; Puglisi F; Contillo A; Pezzella G; Orecchia S; Beccaglia P;
Support Care Cancer; 2007 Sep; 15(9):1057-66. PubMed ID: 17431689
[TBL] [Abstract][Full Text] [Related]
39. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
Patton J; Kuzur M; Liggett W; Miranda F; Varsos H; Porter L
Oncologist; 2004; 9(1):90-6. PubMed ID: 14755018
[TBL] [Abstract][Full Text] [Related]
40. Phase III clinical trials with darbepoetin: implications for clinicians.
Glaspy J
Best Pract Res Clin Haematol; 2005; 18(3):407-16. PubMed ID: 15792914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
